retinal degenerative diseases

Nanoscope Therapeutics Appoints New Chief Medical Officer

by | Apr 26, 2024
Dallas-based Nanoscope said Dr. Allen C. Ho will help define the strategy of developing its gene mutation-agnostic therapies. Ho is attending surgeon and director of retina research at Wills Eye Hospital and co-director of the Wills Eye Hospital Retina Service.
MORE
Nanoscope Therapeutics Bolsters Board with Addition of Ophthalmic Veteran as Strategic Adviser
by | Mar 22, 2023
Nanoscope Therapeutics has enlisted the expertise of Vicente Anido Jr., Ph.D. to help the company advance its goal of developing sight-restoring gene therapies for retinal degenerative diseases. Anido's appointment as a strategic adviser is expected to support Nanoscope's clinical and corporate strategies, especially as the company progresses towards the potential commercialization of MCO-010.
MORE
Nanoscope Therapeutics Names New Vice President of Quality
by | Jan 11, 2023

Nanoscope Therapeutics Inc., a Dallas-based clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, has appointed Massoud Motamed, Ph.D., as vice president of quality.

Motamed brings nearly a decade of CGMP quality and compliance experience, including extensive experience in manufacturing and regulatory review of gene therapy products....

MORE
Protecting your privacy. We have strengthened our Privacy Policy to better protect you. This Policy includes our use of cookies to give you the best online experience and provide functionality essential to our services. By clicking ‘I Accept’ or by continuing to use our website, you are consenting to our Privacy Policy.